Jason Campagna

Company: Q32 Bio

Job title: Chief Medical Officer


The Clinical Promise of Tissue Targeted Complement Therapeutics 10:40 am

Exploring Q32’s approach in utilizing tissue targeted therapies for complement mediated diseases ADX-097’s ability to block complement activity whilst persevering natural immune responses Exploring the benefits and the future promise of tissue targeted therapeutics in the complement industry.Read more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.